Literature DB >> 19787236

Tumor necrosis factor-related apoptosis-inducing ligand induces apoptotic cell death through c-Jun NH2-terminal kinase activation in squamous cell carcinoma cells.

Takenori Noutomi1, Mizue Itoh, Hiroko Toyota, Eiko Takada, Junichiro Mizuguchi.   

Abstract

Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) induces apoptosis in MIT6 cells derived from primary oral squamous cell carcinoma (OSCC), whereas it does not induce apoptosis in MIL6 cells derived from metastases. The present studies were performed to examine whether activation of c-Jun NH2-terminal kinase (JNK) is implicated in the differential sensitivity to TRAIL-induced apoptosis. The TRAIL-induced JNK activation in MIT6 cells was stronger than in MIL6 cells, as assessed by Western blotting using antibodies specific for phospho-JNK. To evaluate the role of JNK1 in TRAIL-induced cell death, one clone expressing the dominant-negative form of JNK1 (dnJNK1) was established. The dnJNK1-expressing cells and MIL6 cells expressed TRAIL protein at levels similar to or even greater than MIT6 cells did. When cell death was assessed by annexin V staining and mitochondrial membrane potential, kinetic studies demonstrated that the dnJNK1-expressing cells were substantially more resistant to 100 ng/ml TRAIL, comparable to MIL6 cells, at 36 and 48 h after stimulation. Collectively, the primary OSCC cell line, MIT6, is sensitive to TRAIL but its metastatic line MIL6 is resistant to TRAIL exposure. Thus, the underlying molecular mechanism of TRAIL-induced cell death involves JNK activation. These results suggest that the acquisition of TRAIL resistance provides some metastatic capacity to primary tumors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19787236     DOI: 10.3892/or_00000551

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  8 in total

1.  The negative prognostic value of TRAIL overexpression in oral squamous cell carcinomas does not preclude the potential therapeutic use of recombinant TRAIL.

Authors:  Francesco Carinci; Lorenzo Monasta; Corrado Rubini; Daniela Stramazzotti; Annalisa Palmieri; Elisabetta Melloni; Alex Knowles; Luca Ronfani; Giorgio Zauli; Paola Secchiero
Journal:  Invest New Drugs       Date:  2010-11-18       Impact factor: 3.850

Review 2.  Anoikis mediators in oral squamous cell carcinoma.

Authors:  J Bunek; P Kamarajan; Y L Kapila
Journal:  Oral Dis       Date:  2010-11-29       Impact factor: 3.511

3.  Inhibition of nuclear factor-kappa B differentially affects thyroid cancer cell growth, apoptosis, and invasion.

Authors:  Kevin T Bauerle; Rebecca E Schweppe; Bryan R Haugen
Journal:  Mol Cancer       Date:  2010-05-21       Impact factor: 27.401

4.  JNK1/2 expression and modulation of STAT3 signaling in oral cancer.

Authors:  Ioannis Gkouveris; Nikolaos Nikitakis; Maria Karanikou; George Rassidakis; Alexandra Sklavounou
Journal:  Oncol Lett       Date:  2016-05-24       Impact factor: 2.967

5.  Extracellular matrix proteins modulate antimigratory and apoptotic effects of Doxorubicin.

Authors:  Georges Said; Marie Guilbert; Hamid Morjani; Roselyne Garnotel; Pierre Jeannesson; Hassan El Btaouri
Journal:  Chemother Res Pract       Date:  2012-07-01

6.  TAK1 is required for survival of mouse fibroblasts treated with TRAIL, and does so by NF-kappaB dependent induction of cFLIPL.

Authors:  Josep Maria Lluis; Ulrich Nachbur; Wendy Diane Cook; Ian Edward Gentle; Donia Moujalled; Maryline Moulin; Wendy Wei-Lynn Wong; Nufail Khan; Diep Chau; Bernard Andrew Callus; James Edward Vince; John Silke; David Lawrence Vaux
Journal:  PLoS One       Date:  2010-01-08       Impact factor: 3.240

7.  TRAIL induces apoptosis in oral squamous carcinoma cells--a crosstalk with oncogenic Ras regulated cell surface expression of death receptor 5.

Authors:  Jun-Jie Chen; Constantinos M Mikelis; Yaqin Zhang; J Silvio Gutkind; Baolin Zhang
Journal:  Oncotarget       Date:  2013-02

8.  Cytokines and tumor metastasis gene variants in oral cancer and precancer in Puerto Rico.

Authors:  Esther Erdei; Li Luo; Huiping Sheng; Erika Maestas; Kirsten A M White; Amanda Mackey; Yan Dong; Marianne Berwick; Douglas E Morse
Journal:  PLoS One       Date:  2013-11-20       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.